Salix scores another FDA green light with approval for angioedema med Ruconest

In its second FDA nod this week, Salix Pharmaceuticals ($SLXP) won the go-ahead for Ruconest, its first-in-class treatment for a rare genetic disease, hereditary angioedema. On Monday, the agency approved broader use of the constipation drug Relistor in patients using opioids for chronic pain. Story